ESR1 and breast carcinoma: Because chemo and immunotherapy are not recommended in the first line for the treatment of LumB breast cancer, known to be estrogen-dependent, we used tamoxifen, an estrogen receptor inhibitor commonly used clinically and anti-kinase inhibitors, increasingly used in personalized medicine like alpelisib [23].